MENLO PARK, Calif., March 6, 2013 /PRNewswire/ -- Facebook announced today that Susan Desmond-Hellmann, M.D., M.P.H., chancellor of the University of California, San Francisco (UCSF), has been elected to the company's board of directors.
"Sue has a great track record of building and managing a diverse set of organizations, so her insights will be valuable as we continue to expand into new areas," said Mark Zuckerberg, founder and CEO of Facebook. "Her experience shaping public policy and operating public companies fits well with the rest of the board and will make us an even stronger company."
"I've always been drawn to organizations that do ground-breaking work," said Desmond-Hellmann. "Facebook has an ambitious mission and long-term vision of innovation that is transforming how people connect with one another. I'm proud to be part of a company that is serving such an important purpose in the world."
As UCSF Chancellor, Desmond-Hellmann oversees all aspects of the university and medical center's strategy and operations. She previously served as president, product development at the biotechnology pioneer, Genentech. In this role, she was responsible for Genentech's pre-clinical and clinical development, process research and development, business development and product portfolio management. During her 14 years with the company, Desmond-Hellmann brought numerous cutting-edge cancer medicines to market to help people battle the disease.Desmond-Hellmann completed her clinical training at UCSF and is board-certified in internal medicine and medical oncology. During her training at UCSF, she spent two years as a visiting faculty member at the Uganda Cancer Institute, studying HIV/AIDS and cancer. She also holds a master's degree in public health from the University of California, Berkeley. Desmond-Hellmann is on the board of directors for Procter & Gamble, and she also serves as a trustee for the Howard Hughes Medical Institute, a nonprofit media research organization.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV